Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: Dose-response effectiveness and extended safety testing in rhesus monkeys

Keyphrases

• Dose-response 100%
• Virus Vaccine 100%
• Yellow Fever 100%
• Japanese Encephalitis Virus 100%
• Rhesus Monkey 100%
• Safety Testing 100%
• Vaccine Dose 100%
• Response Effectiveness 100%
• Monkey 50%
• ChimeraX 50%
• Neutralizing Antibodies 33%
• Viremia 25%
• Encephalitis 16%
• Human Vaccines 16%
• 17D Vaccine 16%
• SA14-14-2 16%
• Cellular Immunity 8%
• Humoral Immunity 8%
• Fold Increase 8%
• Virus 8%
• Immune Response 8%
• Illness 8%
• Immunogenicity 8%
• Spinal Cord 8%
• Live Attenuated 8%
• Vaccine Strain 8%
• Wild Strain 8%
• Amino Acid Residues 8%
• Sham 8%
• Virus Strains 8%
• Neurovirulence 8%
• E Protein 8%
• Pathological Lesions 8%
• 4-fold 8%
• Structural Proteins 8%
• Genome Sequencing 8%
• Protective Efficacy 8%
• Lethal Dose 8%
• Cerebrospinal Fluid 8%
• Recombinant Virus 8%
• Response to Vaccination 8%
• Lung Cells 8%
• Envelope Gene 8%
• Between-day 8%
• Low-level Viremia 8%
• Standardized Tests 8%
• Preclinical Efficacy 8%
• Subcutaneous Route 8%
• Rhesus 8%
• Lesion Score 8%
• Attenuated Strain 8%
• Brain Lesions 8%
• Homologous Vaccine 8%
• Preclinical Safety 8%

Immunology and Microbiology

• Dose Response 100%
• Rhesus Monkey 100%
• Japanese Encephalitis Virus Group 100%
• Japanese Encephalitis Virus 100%
• Yellow Fever Virus 100%
• Japanese Encephalitis Vaccine 100%
• Neutralizing Antibody 36%
• Viremia 36%
• Wild Type 27%
• Encephalitis 18%
• Yellow Fever 18%
• Humoral Immunity 9%
• Adoptive Immunity 9%
• Antibody Response 9%
• Immune Response 9%
• Immunogenicity 9%
• Type Strain 9%
• Antibody Titer 9%
• Spinal Cord 9%
• Env (Gene) 9%
• Recombinant Virus 9%
• Cerebrospinal Fluid 9%
• Amino Acid 9%
• Structural Protein 9%
• LD50 9%